ArticleBMC cancer2025
Correlation between EpCAM expression and cervical lymph node metastasis in papillary thyroid carcinoma: a study integrating ultrasonographic features.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesThe epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein that is overexpressed in various epithelial tumors and has been associated with tumor aggressiveness and unfavorable prognosis. This study aimed to explore the association between ultrasonic characteristics and EpCAM expression in papillary thyroid carcinoma (PTC), as well as the value in predicting the risk of cervical lymph node metastasis (CLNM).
methodsParticipants with suspected thyroid cancer underwent conventional and contrast-enhanced ultrasonography (CEUS) before surgery. Age, sex, and nodule features in ultrasound were recorded. Participants were classified based on the presence of CLNM. EpCAM expression was detected using immunohistochemistry. The risk predictors of CLNM were evaluated by using univariate and multivariate Cox model.
resultsThe final dataset included 53 participants, of whom 27(50.94%) had CLNM, while 26(49.06%) did not. The EpCAM-positive area (p < 0.001), score (p < 0.001), and nuclear expression (p = 0.027) were significantly different between the CLNM and non-CLNM groups. Receiver operating characteristic curve analysis showed that EpCAM score with 4.5 had sensitivity and specificity of 85.2% and 76.9%, respectively, for diagnosing CLNM. Multivariate logistic regression results showed that overexpression EpCAM (score ≧ 4.5) [OR:46.54, p = 0.007], tumor size ≧ 1.05 cm [OR:14.21,p = 0.01] and extrathyroidal extension (ETE) on CEUS [OR:113.33, p = 0.01] were independent risk factors of CLNM. Overexpression of EpCAM (62.07%, 18/29) correlated with ETE of PTC confirmed by postoperative pathology (p = 0.01, 0.027). No significant difference in PTC histological variants was detected based on EpCAM expression (p = 0.05).
conclusionsEpCAM overexpression demonstrated a significant association with ETE and CLNM in PTC. The integration of ultrasonography with EpCAM expression profiling offers A promising multiparameter diagnostic model to enhance predictive accuracy. Further studies evaluating EpCAM expression in fine-needle aspiration biopsy (FNAB) samples are required to determine its possible preoperative predictive value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.